Have a feature idea you'd love to see implemented?
Let us know!
SWTX SpringWorks Therapeutics Inc
Price (delayed)
$29.11
Market cap
$2.16B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$4.44
Enterprise value
$2.09B
SpringWorks is a clinical-stage biopharmaceutical company applying a precision medicine approach to acquiring, developing and commercializing life-changing medicines for underserved patient populations suffering from devastating rare diseases and cancer. SpringWorks
Highlights
SpringWorks Therapeutics's equity has increased by 23% YoY
SWTX's EPS is up by 14% from the previous quarter and by 11% YoY
SWTX's quick ratio is down by 34% year-on-year but it is up by 14% since the previous quarter
SWTX's debt is up by 8% since the previous quarter but it is down by 7% year-on-year
Key stats
What are the main financial stats of SWTX
Market
Valuations
Earnings
Shares outstanding
74.27M
Market cap
$2.16B
Enterprise value
$2.09B
Price to earnings (P/E)
N/A
Price to book (P/B)
3.87
Price to sales (P/S)
25.03
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
24.23
Revenue
$86.19M
EBIT
-$301.06M
EBITDA
-$296.7M
Free cash flow
-$236.76M
Per share
Balance sheet
Liquidity
EPS
-$4.44
Free cash flow per share
-$3.19
Book value per share
$7.51
Revenue per share
$1.16
TBVPS
$8.33
Total assets
$617.33M
Total liabilities
$60.6M
Debt
$7.06M
Equity
$556.73M
Working capital
$376.82M
Debt to equity
0.01
Current ratio
7.91
Quick ratio
7.5
Net debt/EBITDA
0.25
Margins
Efficiency
Dividend
EBITDA margin
-344.3%
Gross margin
95.3%
Net margin
-349.3%
Operating margin
-372.8%
Return on assets
-48.8%
Return on equity
-56.1%
Return on invested capital
-68.1%
Return on capital employed
-53.5%
Return on sales
-349.3%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
SWTX stock price
How has the SpringWorks Therapeutics stock price performed over time
Intraday
1.75%
1 week
-5.43%
1 month
-9.46%
1 year
28.13%
YTD
-20.25%
QTD
-9.14%
Financial performance
How have SpringWorks Therapeutics's revenue and profit performed over time
Revenue
$86.19M
Gross profit
$82.11M
Operating income
-$321.31M
Net income
-$301.06M
Gross margin
95.3%
Net margin
-349.3%
SWTX's operating margin has soared by 73% from the previous quarter
SWTX's net margin has surged by 73% since the previous quarter
The net income has grown by 11% from the previous quarter
The operating income has grown by 11% from the previous quarter but it has contracted by 3.4% YoY
Growth
What is SpringWorks Therapeutics's growth rate over time
Valuation
What is SpringWorks Therapeutics stock price valuation
P/E
N/A
P/B
3.87
P/S
25.03
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
24.23
SWTX's EPS is up by 14% from the previous quarter and by 11% YoY
The P/B is 26% below the 5-year quarterly average of 5.2 and 18% below the last 4 quarters average of 4.7
SpringWorks Therapeutics's equity has increased by 23% YoY
Efficiency
How efficient is SpringWorks Therapeutics business performance
SWTX's ROS has soared by 73% from the previous quarter
The company's return on invested capital rose by 17% QoQ and by 15% YoY
The ROE has grown by 16% from the previous quarter
SWTX's ROA is up by 15% from the previous quarter
Dividends
What is SWTX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for SWTX.
Financial health
How did SpringWorks Therapeutics financials performed over time
SWTX's quick ratio is down by 34% year-on-year but it is up by 14% since the previous quarter
SWTX's total liabilities is down by 32% from the previous quarter and by 8% YoY
SWTX's debt is 99% smaller than its equity
The debt to equity has plunged by 50% YoY
SpringWorks Therapeutics's equity has increased by 23% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.